Recently, we reported that a dipeptidyl peptidase 4 inhibitor improves hepatic steatosis as well as insulin resistance through AMP-activated protein kinase (AMPK)- and JNK-dependent inhibition of LECT2 expression [11]. Here, MAPK8 is linked to Hepatic steatosis.